While pancreas transplantation has evolved within two decades from a frustrating and poorly-accepted therapeutic option to a highly successful procedure, the respective benefits of the successive surgical and immunosuppressive developments have remained unclear. The aim of this study was to determine using an evidence-based methodology, which novel approaches have contributed to the current results and whether pancreas transplantation is cost-effective. Out of 2481 articles, 102 analyzed either surgical or immunosuppressive aspects of pancreas transplantation. Urological complications were more frequent in bladder over enteric drainage (range: 62-63% vs. 12-20%, p = 0.0001), but without significant difference in patient or graft survival. Portal drainage was associated with a trend toward fewer complications and better hyperinsulinemia control over systemic drainage in retrospective studies. Immunosuppression combining induction therapy, a calcineurin inhibitor, mycophenolate mophetil (MMF) and corticosteroids were associated with a 40% decreased incidence of rejection (p = 0.01) and an increase in graft survival above 90% at 1 year (p < 0.05). Pancreas transplantation is highly cost-effective compared to conservative alternatives. We conclude that despite a paucity of large studies, enteric drainage should be recommended but the benefits of portal venous drainage remain debated. Quadruple immunosuppression protocols including induction therapy should be the standard regimen.
Introduction
Kelly et al. performed the first pancreas transplantation in 1966 at the University of Minnesota (1) . Until the early 80s, the reported worldwide series were characterized by poor success rates due to a high incidence of surgical complications and irreversible rejection (2) (3) (4) (5) . From the mid-1980s, innovative technical and anti-rejection strategies enabled significant improvement in graft function and survival. The introduction of exocrine bladder drainage was associated with a decreased incidence of post-operative complications mostly related to earlier detection of rejection through monitoring of urine amylase levels (6) . The availability of Cyclosporin A (CyA) in 1983 undoubtedly further contributed to better graft survival (7) . Many recent innovations in pancreas transplantation have contributed to improvements with a 93% 1-year graft and patient survival rates reported in 2002, by the International Pancreas Transplant Registry (IPTR) (8, 9) . However, which interventions have provided benefits remains controversial and no evidence-based recommendation on a surgical procedure or immunosuppression protocol is currently available.
The need to base clinical decisions on the best available scientific evidence is supported by the importance of quality control and cost-containment, as well as the increasing patient interest for the best available treatment. Evidencebased surgery is a modern approach to achieve objective criteria for indications and operation techniques. Alternative therapies such as islet cell transplantation (10) or insulin pump devices as less invasive procedures, may challenge the value of pancreas transplantation in the near future. Therefore, a critical assessment of the current results of pancreas transplantation appears timely.
The aim of this study was to perform an evidence-based analysis of simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone. We assessed the outcome according to the different operation techniques and immunosuppression protocols, and looked at cost-efficiency.
Materials and Methods

Literature research
An electronic search of the Medline database from 1992 to December 2004 was performed to identify all relevant articles comparing surgical techniques and immunosuppression protocols in pancreas transplantation. The following search terms in the medical subject heading, title and abstract were used in various combinations to refine the search: pancreas, transplantation, drainage, bladder drainage, enteric drainage, portal drainage, systemic drainage, immunosuppression and cost analysis. In addition, we performed manual cross-referencing to identify further articles. All studies that compared different surgical techniques and immunosuppression regimens in SPK were included. Furthermore, we included all articles on cost analysis and pancreas transplantation alone.
Besides the Medline database, another important source of information about pancreas transplantation since 1980 is the International Pancreas Transplant Registry (IPTR), held at the University of Minnesota (8) . The database is said to sample about 95% of all pancreas transplantations performed worldwide, but its value is somewhat limited due to the voluntary self-declaration nature of the data collection. The registry date was used in the present analysis only for epidemiologic information.
Study review and quality grading
All studies were reviewed independently by two of the authors (ND and MS) as requested in proper evidence-based analysis (11). Discrepancy between the reviewers was resolved by consensus. We included only published full-length papers in English. Review articles, registry data, abstracts and publications of abstract character were excluded. If more than one study by the same group was published with data repetition, only the most recent publication was included in the analysis. The studies were assessed for the following endpoints: 1-year graft survival, 1-year patient survival rate, complication rate, pancreas leakage rate and rejection rate.
All studies were classified according to their level of evidence using the classification proposed by the Oxford Centre for Evidence-based Medicine (Table 1 ) (11-13). Based on the level of evidence, grades of recommendation (A, B, C, D) were given. Thereby, grade A provides the best and strongest recommendation since it is based on the highest level of evidence (RCT and meta-analysis). The next levels of recommendations are grade B and C which are used for lower study qualities such as cohort (grade B) and case control studies (grade C). Finally, grade D demonstrates the lowest recommendation since it is based only on expert opinions. Table 3) . Two of them were prospective randomized trials (14, 15) , while the other one was a retrospective study (16) . The remaining 11 studies (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) analyzed the outcome according to different exocrine drainage (bladder vs. enteric) techniques (Table 2 and 4). They were all ranked level 2b. No prospective randomized trial was identified in this group.
Out of the 66 studies analyzing immunosuppression protocols in SPK transplantation, we established subgroups to evaluate induction therapy (Table 5 ), calcineurin inhibitors (Table 6 ), anti-proliferative agents (Table 7) and corticosteroids. Excluded were 29 studies with abstract characters only, 20 reviews and five center reports without comparison with different protocols. Of the selected 10 papers, six were ranked level 1b (14, (28) (29) (30) (31) (32) and four level 2b (23, (33) (34) (35) .
While more than 18 000 SPK have been performed worldwide (8, 36) , only few centers have developed a large program (>10 transplants/year). This may explain the paucity of convincing studies available in this field. For example, out of 2481 studies only 48 RCTs could be identified in the Medline database. In addition, most of these studies were published by the same seven centers. As a result, an evidence-based analysis could be based only on a few studies fulfilling the criteria, and the lack of RCTs did not allow us to perform a meta-analysis.
What is the optimal exocrine drainage technique? Bladder or enteric drainage? Historically, SPK was associated with a high morbidity due to intra-abdominal sepsis. The anastomotic leaks were believed to be due to duodenal rejection, and the technique was abandoned (7). Bladder drainage was introduced in 1983 in order to reduce the incidence of postoperative technical complications, in particular a reduction in intra-abdominal sepsis (7) . This technique allowed the early detection of graft rejection by measuring serial urine (27) Enteric drainage (n = 11) 0 10 91 100 § UTI. * Statistical significance (p < 0.05). amylase, but complications like urinary tract infections in up to 62% of bladder-drained patients remained a significant clinical problem (24) .With the introduction of new immunosuppressive agents like tacrolimus and mycophenolate mophetil (MMF), the rejection rate dropped and enteric drainage was used again increasingly (24) .
No RCT comparing bladder versus enteric drainage technique was identified; therefore the analysis was based on six retrospective studies ranked level 2b (Table 2 ) (22) (23) (24) (25) (26) (27) . Studies designed to compare systemic bladder with portal enteric drainage were analyzed separately (see below). The pooled number of patients in the six trials was 700 in the bladder-drained group and 327 in the entericdrained group. The smallest number of patients in a study was 11 and the largest 388. One-year pancreas graft survival ranged from 78% to 94% in the bladder versus 74% to 93% in the enteric drainage group. There was no statistical difference regarding graft survival between the two techniques in five studies (22, 23, (25) (26) (27) . One study by Sollinger et al. (24) reported a significantly improved 1-year pancreas graft survival in the bladder group: 82% in the bladder group (n = 136) vs. 74% in the enteric group (n = 70), (p = 0.03). However, patient survival data revealed no differences ranging from 92% to 100% in both groups.
Among these six studies (22) (23) (24) (25) (26) (27) , the urinary tract infection rates ranged from 48% to 75% in bladder versus 12% to 37% (26, 27) in enteric drainage groups (p = 0.0001) (27) . Moreover, in two trials (22, 24) , the urological complication rates were significantly higher in the bladder drainage group compared to the enteric drainage group (62% vs. 12%, p = 0.0001 and 63% vs. 20%, p = 0.0001), respectively.
Pancreas leakage was reported in four studies (22, 24, 26, 27) and was significantly lower for enteric drainage (5% vs. 12%, p = 0.06) in one report (22) . In the three others (24, 26, 27) , Kuo et al. (26) did not find any leakage; Sollinger et al. (24) reported 17% in the bladder versus 5% in the enteric group, and Pearson et al. (27) 6% in the bladder versus 10% in the enteric group, without statistical significance. Two trials (22, 24) assessed the rate of opportunistic infections, which were significantly lower in the enteric group; opportunistic infection: 12% versus 33%, p = 0.002 (24) ; and 15% versus 28%, p = 0.03 (22) .
The rejection rate was assessed in three trials (23, 24, 26) disclosing a large variability of rejection rates ranging between 16% and 87% depending on the immunological era in which the trial was performed. However, within the trials there was no difference between the two different types of drainage regarding rejection rate as reported by Sollinger et al. (24), who found a 45% rejection rate in the bladder group versus 39% in the enteric group at 1 year. 
What is the optimal venous drainage? Portal or systemic venous drainage?
The idea behind portal venous delivery of insulin relies on the concept of avoiding potential complications related to the release of insulin directly into the systemic circulation with associated hyperinsulinemia leading to accelerated arteriosclerosis and dyslipidemia. While some experimental models have suggested a benefit for portal drainage of insulin (37), convincing evidence is still lacking in the clinical setting (38) .
Three trials (14) (15) (16) analyzed the outcome of venous drainage technique in enteric-drained patients. Two of them (14, 15) were RCT ranked level 1b, and one was a retrospective study ranked as level 2a (16) ( Table 3 ). The pooled number of patients in the portal group was 107 versus 98 in the systemic group. The 1-year graft survival rates were comparable between both groups ranging from 74% to 76% in the systemic drained group and from 74% to 85% in the portal drained group.
The venous thrombosis rate in the graft ranged from 4% to 7% without differences between the two drainage techniques. There was a trend toward lower surgical complication rates (early laparotomy/bleeding/leakage) in the portal group (18-26% vs. 30-35%).
The rejection rate was similar in the two RCT (14,15) ranging from 29% to 33%. Philosophe et al. (16) analyzed a large cohort of patients with the same immunosuppression protocol (n = 117) and observed a 9% rejection rate in the portal group compared to 45% in the systemic drained group (p = 0.0002). In the same trial, 97 other patients with pancreas after kidney transplantation were assessed as well. The rejection rate was 16% in the portal versus 65% in the systemic drained group (p = 0.0001). Moreover, rejections were milder in the portal group in both SPK and pancreas after kidney transplantation. On the other hand, the rejection rate in the systemic group of this retrospective analysis (16) is high compared to those observed in the RCT (14, 15) which makes the benefit of portal drainage on rejection questionable.
In the two prospective studies (14, 15) , one shows a trend toward lower surgical complication rates observed in the portal drainage groups (4/17 vs.7/17) (15) , and the other a trend toward lower intra-abdominal infections (11% vs. 26%) (14) . The retroperitoneal approach necessary for systemic drainage, but not for portal drainage, may explain these observations. Glycamia control is excellent in both techniques, but after portal drainage less hyperinsulinemia was observed in two retrospective studies including 100 and 60 patients, respectively (17, 20) .
Based on the available data gathered from small series, it can be concluded that portal venous drainage provides only a marginal advantage over systemic drainage. Only trends were documented for lower complication and infection rates favoring portal venous drainage and there were no differences in graft survival. The better insulinemia control was observed only in retrospective studies. This makes a definitive recommendation difficult, but the choice of portal drainage may be suggested. (grade of recommendation C).
According to IPTR data, only 23% of reporting centers (including our own center) performed pancreas transplantation using a portal drainage in 2003 (8). However, despite the relatively small number of transplant centers performing a portal venous drainage, a center more than a technique effect is unlikely to explain the improved results of portal over systemic drainage, and further RCT are needed.
Which combination of venous and exocrine drainage should be selected?
From the various possible combinations of venous and exocrine drainage, data are available only in patients treated with systemic venous bladder exocrine versus portal venous enteric exocrine drainage.
Systemic bladder drainage was compared to portal-enteric drainage in five studies (14, (17) (18) (19) (20) . The total pooled number of patients was 106 in the systemic-bladder drainage group and 84 in the portal-enteric drainage group. There was no statistically significant difference at 1 year in terms of graft (range: 70-100%, irrespective of the group) and patient (range: 82-100%) survival rates.
Gaber et al. (17) reported less urinary tract infections in the enteric drainage group in their series of 115 patients (89% vs. 26%, p < 0.0001). However, all other trials (18) (19) (20) (21) failed to show a significant reduction of urinary tract infections in the enteric group (Table 2) . Pancreas leakage was only assessed in two trials (17, 19) showing comparable rates, that is, 0-4% in the systemic bladder versus 0-6% in the portal enteric group. Sollinger et al. (24) reported a conversion rate of 24% (n = 388) from bladder to enteric drainage at 5 year due to urological complications.
There were no differences in rejection rates among the five trials (14, (17) (18) (19) (20) . Two studies (17, 20) reported lower rates of acidosis in the portal enteric group reaching statistically significant values in one trial (75% vs. 8%, p < 0.005) (20) . The same studies (17, 20) reported less hyperinsulinemia in the portal compared to systemic drainage groups with significant lower fasting insulin levels (11.0 vs. 55.3 U/mL; p = 0.01) (17) The benefit of combined portal and enteric drainage appears to be related mostly to lower urological complication rates than to better controls of rejection or diabetes and this appears mainly due to the enteric drainage, while the impact of portal drainage remains difficult to evaluate. The influence of recently-introduced immunosuppressive protocols, rather than a specific surgical technique, may also have significantly contributed to improved outcome. The failure to measure urine amylase after enteric drainage was not associated with increased rejection rates supporting the input of novel effective immunosuppressive regimens.
We conclude that the combination of portal venous and enteric exocrine drainage seems superior to systemic venous and bladder-drained pancreas.
(recommendation grade B).
What is the best immunosuppressive regimen minimizing rejection and improving graft survival? Induction therapy (Table 5) : Five trials (23, 30, 32, 35, 39) evaluating induction therapies were identified. Three level 1b trials (30, 32, 39) evaluated the benefit of Daclizumab and ATG versus no-induction therapy. One trial compared T-cell depleting ATG induction therapy versus no-induction therapy in 50 patients who received CyA, azathioprine (AZA) and corticosteroids. One level 1b trial (39) analyzed 219 patients receiving Daclizumab induction therapy intwo different regimens. All studies favored induction therapy with significant reduction of biopsy-proven renal rejection rates from 76% to 36% (p = 0.01) (30) and reduced pancreas rejection rates (range: 3.6-10.3%, p = 0.160). The 1-year graft survival rates of all trials ranged between 84% and 98%. In the no-induction groups the 1-year graft survival ranged from 86% to 90% versus 84% to 96% in the induction groups. There were no statistically significant differences between induction versus no-induction therapy regarding graft and patient survival except for 3-year renal graft survival: 92% versus 82% in no-induction group (p = 0.04) (32) . Anti-proliferative agents (Table 7) : Two RCT (28, 29) and one retrospective study (34) analyzed the outcome in patients with AZA in comparison to MMF. All trials suggested a benefit for the use of MMF regarding rejection rates: 7% versus 24% (p < 0.05), 11% versus 77% (p < 0.01) and 27% versus 39% (p = 0.3). However, patient survival rates were comparable between the groups ranging from 93% to 100%. Graft survival was significantly lower for AZA in the retrospective report (34), 83% versus 95% in the MMF group (p < 0.05), whereas the two prospective trials (28, 29) showed similar high rates of graft survival irrespective of the immunosuppression ranging between 85% and 100%.
Calcineurin inhibitors (
Corticosteroids: All immunosuppression regimens analyzed above included corticosteroids as basis therapy. However, to prevent long-term side effects of steroid therapy such as hyperglycemia and osteoporosis, there has been an increasing interest in favoring steroid-free multimodal immunosuppressive therapy for pancreas transplantation. The rapid elimination of corticosteroids in SPK was analyzed prospectively in 126 patients (40) .
Corticosteroids were discontinued 6 days after transplantation in 40 patients (29%). These patients received either tacrolimus and MMF or tacrolimus and sirolimus. Patient and graft survival rates were compared to a historical control group of SPK recipients (n = 86), who received a quadruple therapy including induction therapy, tacrolimus, MMF and corticosteroids. The rejectionfree survival rate with rapid steroid elimination was 100% in the tacrolimus/sirolimus group, and 95% in the tacrolimus/MMF group (collectively 97.5%), compared to 80% in the historical control group (p = 0.034). Corticosteroids still belongs to basis immunosuppression, but early withdrawal seems safe.
From all these studies on immunosuppression, it can be concluded that both calcineurin inhibitors (Cya and tacrolimus) confer similar protection against rejection with a possible benefit in graft survival rates for tacrolimus. MMF is superior to AZA regarding rejection rates, and induction therapy decreases rejection rates and increases graft survival. Rapid corticosteroid elimination appears to be a safe strategy. The use of either calcineurin inhibitor in combination with MMF and induction therapy should be recommended (Recommendation grade A).
According to IPTR registry data (8), the majority of pancreas transplant centers are using a regimen including an induction therapy, tacrolimus, MMF or derivate and steroids, which is consistent with the evidence-based analysis.
Is simultaneous pancreas kidney transplantation cost-effective?
We identified four studies assessing different aspects of cost-effectiveness regarding pancreas transplantation (41) (42) (43) (44) . Douzdjian et al. (42) assessed the cost of different treatment strategies for diabetic patients with end-stage renal disease comparing costs associated to dialysis alone, kidney transplant alone (living or cadaver donor) and SPK transplantation. The analysis was based on a 5-year model. The outcome criteria used in the model were cost, utility and cost-utility. The expected cost per quality-adjusted year for each of the treatment strategies in the model were $317 746 for dialysis, $156 042 for cadaver kidney transplant, $123 923 for living kidney transplant and $102 422 for SPK transplantation. SPK transplantation remained the optimal strategy even with the use of varying survival probabilities, various costs and utilities over plausible ranges by means of one-way sensitivity analysis. With the use of the same 5-year model, this group also analyzed the cost and utility of living kidney alone followed by pancreas transplantation (pancreas after kidney) versus SPK transplantation. The expected 5-year costs were comparable in both groups. When adjusted for utility, living kidney alone followed by pancreas transplantation yielded a cost of $153 911 and SPK a cost of $110 828 per quality-adjusted year (42). Based on the analysis of the United Network of Organ Sharing (UNOS) data between 1995 and 2000, respectively (45, 46) , the overall risk of death after SPK transplantation lied between 0.29 and 0.43 compared with patients remaining on the waiting list (p < 0.001).
We conclude that a successful SPK transplantation is costeffective, and together with improved quality of life, is superior to alternative treatment strategies such as dialysis or kidney transplant alone and insulin therapy (recommendation grade C).
Is pancreas transplantation alone a viable therapeutic strategy?
Intensive insulin therapy delays the onset of secondary diabetic complications, but does not substitute for normal beta-cells functions (47) . Thus only the replacement by a pancreas allows to restore normal glucose metabolism. For this reason, pancreas transplantation alone has be considered as an option in diabetic patients without nephropathy (48) .
There are currently no prospective clinical trials available on pancreas transplantation alone, and most of the data come from the IPTR and UNOS databases (8, 36 .2 more quality-adjusted life-years compared to patients treated with standard insulin therapy. The incremental costs (charges) for early pancreas transplantation over standard therapy were estimated to be about $56 600/quality-adjusted life-year for the baseline case. Pancreas transplant costs were also a very sensitive parameter in the cost-utility analysis. The authors concluded that a trial in selected type 1 diabetic patients at risk for renal and retinal disease should be considered.
All authors agree on the need to perform a prospective randomized study on pancreas transplantation alone in diabetics with preserved renal function compared to conservative therapy. Until such data become available, we can only recommend pancreas transplantation alone in selected patients (recommendation grade C).
Does pancreas transplantation alone reverse diabetic nephropathy?
Fioretto et al. (48) have shown that prolonged euglycemia provided by pancreas transplantation alone in diabetic patients may reverse diabetic nephropathy. This observation was made in eight patients, who were followed over 10 years after pancreas transplantation alone. Pancreas transplantation could reverse the lesions of diabetic nephropathy, but reversal required more than 5 years of normoglycemia. The beneficial effects were evident despite the nephrotoxic effects of immunosuppressive agents. On the other hand, Mazur et al. (50) investigated the renal function in 23 patients after pancreas transplantation and showed a decline in the native renal function in the majority of patients regardless of the pre-transplant glomerular filtration rates.
We conclude that pancreas transplantation alone may be cost-effective in selected labile nonuremic diabetics, although the authors failed to show a patient-survival benefit (recommandation grade C). A prospective comparison of the outcome of type 1 diabetic patients with and without pancreas transplantation alone should be performed with special regard to the progression of kidney function.
Concluding Remarks
Despite the paucity of RCT studies and many low-quality studies on pancreas transplantation, this evidence-based methodology appears to be a valuable tool to suggest recommendations on various surgical and immunological options available.
The present review allows six important statements summarized in Table 8 . Except a recommendation A for immunosuppression, the level of evidence for these recommendations and statements is limited to B or C. Despite a few large series with very convincing data (17, 24, 25, 31, 32, 51) , the total number of patients analyzed remains relatively low. We conclude, however, that based on this best available scientific evidence, SPK is currently the gold standard to which other therapies should be compared.
